Disease modifying drugs for rheumatological diseases: a brief history of everything

被引:6
|
作者
Giles, Joanna L. [1 ]
Polak, Oktawia J. [1 ]
Landon, John [1 ]
机构
[1] MicroPharm Ltd, Newcastle Emlyn, Carmarthenshire, Australia
来源
关键词
TUMOR-NECROSIS-FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ACTIVE PSORIATIC-ARTHRITIS; B-CELL DEPLETION; FREE H CHAINS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; SYNOVIAL-FLUID; FACTOR-ALPHA;
D O I
10.1016/bs.apcsb.2019.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The rheumatological diseases are a group of chronic, painful, degenerative and debilitating conditions with an increasing prevalence across the globe. The pathogenesis of these disorders is complex, overlapping and not fully understood. As such, it is difficult and time consuming to achieve correct diagnosis and complete remission for an individual patient. In this review we describe the most common forms of inflammatory arthritis and discuss how the management and treatment options for these rheumatic diseases have developed over time. We outline the successes and the limitations of current treatment regimens and discuss the economic burden of the current options. With advancements in understanding of disease mechanisms, we discuss the importance of the biologics revolution in the context of rheumatological disease and how the development of biosimilars and small molecule inhibitors will impact current treatment options in order to alleviate some of the cost burden of biological therapies. The ideal treatment strategy for the future would involve personalized and predictive medicine where by treatments can be tailored to an individual patient's needs in order to achieve fast and successful remission with no adverse events.
引用
收藏
页码:313 / 348
页数:36
相关论文
共 50 条
  • [11] Inflammatory bowel disease in paediatric rheumatological diseases
    Tas, Ozen
    Aydin, Fatma
    Kuloglu, Zarife
    Kirsaclioglu, Ceyda Tuna
    Bahceci, Onur
    Aydin, Betul oksuz
    Sarisoy, Dogacan
    Ozcakar, Zeynep Birsin
    CLINICAL RHEUMATOLOGY, 2025,
  • [12] Disease-Modifying Antirheumatic Drugs (DMARDs) Utilisation in Autoimmune Rheumatic Diseases
    Anghel, L.
    Leucuta, D.
    Farcas, A.
    Oprean, R.
    DRUG SAFETY, 2017, 40 (10) : 984 - 985
  • [13] DISEASE MODIFYING OSTEOARTHRITIS DRUGS
    Meray, Jale
    Gunendi, Zafer
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2011, 14 : 73 - 77
  • [14] Disease-modifying drugs
    不详
    BRITISH JOURNAL OF RHEUMATOLOGY, 1996, 35 (11): : 1043 - 1043
  • [15] Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
    Palacios, Carlo Foppiano
    Chowdhary, Vaidehi
    Hao, Ritche
    Danve, Abhijeet
    Malinis, Maricar
    PLOS ONE, 2024, 19 (07):
  • [16] Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases
    Fazaa, Alia
    Makhlouf, Yasmine
    Ben Ouhiba, Amad
    Miladi, Saoussen
    Sellami, Mariem
    Ouenniche, Kmar
    Souabni, Leila
    Kassab, Salma
    Chekili, Selma
    Zakraoui, Leith
    Ben Abdelghani, Kawther
    Laatar, Ahmed
    THERAPIE, 2021, 76 (05): : 467 - 474
  • [17] Disease modifying antirheumatic drugs and pregnancy
    Uhl, K
    Kennedy, DL
    Gilliland, WR
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (02) : 400 - 401
  • [18] Disease Modifying Drugs Targeting β-Amyloid
    Ozudogru, S. N.
    Lippa, C. F.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2012, 27 (05): : 296 - 300
  • [19] Disease-modifying antirheumatic drugs
    Lambert, David G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2012, 13 (03): : 128 - 130
  • [20] BIOLOGIC DISEASE MODIFYING DRUGS IN SLE
    Dall'Era, Maria
    LUPUS SCIENCE & MEDICINE, 2023, 10 (SUPPL_2): : A2 - A3